Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy
The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy.
Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded.
Significant mean reductions from baseline were seen at month 12 for HbA1c (–2.2%, n = 59) and FPG (–3.0 mmol/L, n = 59) and mean percent change in fasting TGs (–32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity.
In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume.
KeywordsDiabetes Insulin resistance Leptin Lipodystrophy Metreleptin
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript and take responsibility for the integrity of the work as a whole. Aegerion Pharmaceuticals provided funding for medical writing and/or editing support in the development of this manuscript; Jennifer L. Giel, Ph.D., of inScience Communications, Springer Healthcare (Philadelphia, PA, USA), based on input from authors, wrote the first draft and revised subsequent drafts of the manuscript, and Adrienne M. Schreiber of inScience Communications, Springer Healthcare (Philadelphia, PA, USA) copyedited and styled the manuscript per journal requirements. Aegerion Pharmaceuticals reviewed and provided feedback to the authors. The authors had full editorial control of the manuscript and provided their final approval of all content. Jean-Karl Sirois provided statistical analyses on behalf of Veristat LLC, Montreal, Canada, which was funded by Aegerion Pharmaceuticals, Inc. The authors acknowledge the services of the Clinical Core Laboratory of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health for measurement of leptin levels.
This work was supported by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases. E.A.O. is supported by NIH grant RO-1 DK-088114 as well as UM Lipodystrophy Fund donated by the Sopha Family and White Point Foundation of Turkey.
Compliance with ethical standards
Conflict of interest
E.A.O. has served as a consultant to Aegerion, Akcea, AstraZeneca, and Regeneron, received grants from Aegerion, Akcea, AstraZeneca, Gemphire, GIDynamics, and received non-material support from Aegerion and Boehringer Ingelheim. D.A.V. and D.B.S. have served as consultants to Aegerion Pharmaceuticals. A.L. and G.F. are employees of Aegerion Pharmaceuticals. T.S. is a former employee of Aegerion Pharmaceuticals. R.J.B., E.C., and P.G. declares that they have no conflict of interest.
- 1.R.J. Brown, D. Araujo-Vilar, P.T. Cheung, D. Dunger, A. Garg, M. Jack, L. Mungai, E.A. Oral, N. Patni, K.I. Rother, J. von Schnurbein, E. Sorkina, T. Stanley, C. Vigouroux, M. Wabitsch, R. Williams, T. Yorifuji, The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J. Clin. Endocrinol. Metab. 101, 4500–4511 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Y. Handelsman, E.A. Oral, Z.T. Bloomgarden, R.J. Brown, J.L. Chan, D. Einhorn, A.J. Garber, A. Garg, W.T. Garvey, G. Grunberger, R.R. Henry, N. Lavin, C.D. Tapiador, C. Weyer, The clinical approach to the detection of lipodystrophy—an AACE consensus statement. Endocr. Pract. 19, 107–116 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 5.A. Bingham, G. Mamyrova, K.I. Rother, E. Oral, E. Cochran, A. Premkumar, D. Kleiner, L. James-Newton, I.N. Targoff, J.P. Pandey, D.M. Carrick, N. Sebring, T.P. O’Hanlon, M. Ruiz-Hidalgo, M. Turner, L.B. Gordon, J. Laborda, S.R. Bauer, P.J. Blackshear, L. Imundo, F.W. Miller, L.G. Rider, Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 87, 70–86 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
- 10.M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, H.N. Ginsberg, A.C. Goldberg, W.J. Howard, M.S. Jacobson, P.M. Kris-Etherton, T.A. Lennie, M. Levi, T. Mazzone, S. Pennathur, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292–2333 (2011)CrossRefPubMedGoogle Scholar
- 12.Myalept [Package Insert] (Aegerion Pharmaceuticals, Inc., Cambridge, MA, 2015)Google Scholar
- 15.J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
- 21.K. Ebihara, T. Kusakabe, M. Hirata, H. Masuzaki, F. Miyanaga, N. Kobayashi, T. Tanaka, H. Chusho, T. Miyazawa, T. Hayashi, K. Hosoda, Y. Ogawa, A.M. DePaoli, M. Fukushima, K. Nakao, Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92, 532–541 (2007)CrossRefPubMedGoogle Scholar
- 22.C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, J. Riveline, J. Young, L. Mathivon, F. Travert, D. Morin, J. Cahen, O. Lascols, F. Andreelli, Y. Reznik, E. Mongeois, I. Madelaine, M. Vantyghem, J. Gautier, C. Vigouroux, One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab. 18, 693–697 (2016)CrossRefPubMedGoogle Scholar
- 23.D. Araujo-Vilar, S. Sanchez-Iglesias, C. Guillin-Amarelle, A. Castro, M. Lage, M. Pazos, J.M. Rial, J. Blasco, E. Guillen-Navarro, R. Domingo-Jimenez, M.R. del Campo, B. Gonzalez-Mendez, F.F. Casanueva, Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine 49, 139–147 (2015)CrossRefPubMedGoogle Scholar
- 25.J. Beltrand, M. Beregszaszi, D. Chevenne, G. Sebag, M. De Kerdanet, F. Huet, M. Polak, N. Tubiana-Rufi, D. Lacombe, A.M. De Paoli, C. Levy-Marchal, Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 120, e291–e296 (2007)CrossRefPubMedGoogle Scholar